A new drug knocks down rheumatoid arthritis symptoms in patients who have failed to benefit from other medications, according to a study released online June 29 in TheLancet.
The new findings may clear the way for approval in Europe for the anti-inflammatory drug, called golimumab.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.